TW200413357A - Indolyl derivatives - Google Patents
Indolyl derivatives Download PDFInfo
- Publication number
- TW200413357A TW200413357A TW092132418A TW92132418A TW200413357A TW 200413357 A TW200413357 A TW 200413357A TW 092132418 A TW092132418 A TW 092132418A TW 92132418 A TW92132418 A TW 92132418A TW 200413357 A TW200413357 A TW 200413357A
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- item
- phenyl
- patent application
- scope
- Prior art date
Links
- 125000001041 indolyl group Chemical group 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 150000002148 esters Chemical class 0.000 claims abstract description 17
- -1 isopropyl-phenyl group Chemical group 0.000 claims description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 19
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 15
- 101150014691 PPARA gene Proteins 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 229940086609 Lipase inhibitor Drugs 0.000 claims description 11
- 230000002503 metabolic effect Effects 0.000 claims description 11
- 229960001243 orlistat Drugs 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- MGJSKBDJIVNGRI-UHFFFAOYSA-N 2-(1h-indol-4-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC2=C1C=CN2 MGJSKBDJIVNGRI-UHFFFAOYSA-N 0.000 claims description 6
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 230000003143 atherosclerotic effect Effects 0.000 claims description 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- JRXXEXVXTFEBIY-UHFFFAOYSA-N 3-ethoxypropanoic acid Chemical compound CCOCCC(O)=O JRXXEXVXTFEBIY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 2
- 125000005805 dimethoxy phenyl group Chemical group 0.000 claims description 2
- XBHQOMRKOUANQQ-UHFFFAOYSA-N 2-ethoxypropanoic acid Chemical compound CCOC(C)C(O)=O XBHQOMRKOUANQQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 10
- 239000003925 fat Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000000052 vinegar Substances 0.000 description 8
- 235000021419 vinegar Nutrition 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000012876 carrier material Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229940127470 Lipase Inhibitors Drugs 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 5
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000011737 fluorine Chemical group 0.000 description 4
- 229910052731 fluorine Chemical group 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 150000003335 secondary amines Chemical group 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 150000003512 tertiary amines Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 125000003944 tolyl group Chemical group 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZHKFCGUCHAGTKP-UHFFFAOYSA-N 3-oxido-1,3-oxazol-3-ium Chemical compound [O-][N+]=1C=COC=1 ZHKFCGUCHAGTKP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XVRDITINKCASST-UHFFFAOYSA-N 4-iodo-1h-indole Chemical compound IC1=CC=CC2=C1C=CN2 XVRDITINKCASST-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 101100139845 Caenorhabditis elegans rac-2 gene Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- DXGTUUQHTDOFFQ-UHFFFAOYSA-N [N].C1=CC=C2NC=CC2=C1 Chemical group [N].C1=CC=C2NC=CC2=C1 DXGTUUQHTDOFFQ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical group COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000000068 chlorophenyl group Chemical group 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- VNOQCQYAGYILFN-JTQLQIEISA-N (1S)-1-(9H-fluoren-1-yl)ethanamine Chemical compound C[C@H](N)c1cccc-2c1Cc1ccccc-21 VNOQCQYAGYILFN-JTQLQIEISA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- UYVWNPAMKCDKRB-UHFFFAOYSA-N 1,2,4,5-tetraoxane Chemical compound C1OOCOO1 UYVWNPAMKCDKRB-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- SXWIAEOZZQADEY-UHFFFAOYSA-N 1,3,5-triphenylbenzene Chemical compound C1=CC=CC=C1C1=CC(C=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=C1 SXWIAEOZZQADEY-UHFFFAOYSA-N 0.000 description 1
- LAYXHUOYWYRVDY-UHFFFAOYSA-N 1,3-oxazol-2-yl(phenyl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1=NC=CO1 LAYXHUOYWYRVDY-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VWVZFHRDLPHBEG-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfanylbenzene Chemical group CSC1=CC=C(CCl)C=C1 VWVZFHRDLPHBEG-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- KTHFIEALGAIEFB-UHFFFAOYSA-N 2-(9h-fluoren-1-ylamino)acetic acid Chemical compound C1C2=CC=CC=C2C2=C1C(NCC(=O)O)=CC=C2 KTHFIEALGAIEFB-UHFFFAOYSA-N 0.000 description 1
- TVCXVUHHCUYLGX-UHFFFAOYSA-N 2-Methylpyrrole Chemical compound CC1=CC=CN1 TVCXVUHHCUYLGX-UHFFFAOYSA-N 0.000 description 1
- NBHBTBKRRSYMSL-UHFFFAOYSA-N 2-ethoxy-3-(1H-indol-4-yl)propanoic acid Chemical compound CCOC(C(O)=O)CC1=CC=CC2=C1C=CN2 NBHBTBKRRSYMSL-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- RQCBPOPQTLHDFC-UHFFFAOYSA-N 2-phenyl-1,3-oxazole Chemical compound C1=COC(C=2C=CC=CC=2)=N1 RQCBPOPQTLHDFC-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 1
- KYAXCYQVBBQQHB-UHFFFAOYSA-N 3-methyl-2-phenyl-1h-indole Chemical compound N1C2=CC=CC=C2C(C)=C1C1=CC=CC=C1 KYAXCYQVBBQQHB-UHFFFAOYSA-N 0.000 description 1
- 125000002528 4-isopropyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KWSLGOVYXMQPPX-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenyl]-2h-tetrazole Chemical compound FC(F)(F)C1=CC=CC(C2=NNN=N2)=C1 KWSLGOVYXMQPPX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RJLUKRUFDZWUOR-UHFFFAOYSA-N C(C)(C)N([Li])C(C)C.[Li] Chemical compound C(C)(C)N([Li])C(C)C.[Li] RJLUKRUFDZWUOR-UHFFFAOYSA-N 0.000 description 1
- OFDBDQOUKVEZIE-UHFFFAOYSA-J C(C1=CC=C(C(=O)[O-])C=C1)(=O)[O-].[Mo+4].C(C1=CC=C(C(=O)[O-])C=C1)(=O)[O-] Chemical compound C(C1=CC=C(C(=O)[O-])C=C1)(=O)[O-].[Mo+4].C(C1=CC=C(C(=O)[O-])C=C1)(=O)[O-] OFDBDQOUKVEZIE-UHFFFAOYSA-J 0.000 description 1
- MWMUWOJFZXNKLG-UHFFFAOYSA-N CN(C=O)C.[V] Chemical compound CN(C=O)C.[V] MWMUWOJFZXNKLG-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000001808 Ceanothus spinosus Nutrition 0.000 description 1
- 241001264786 Ceanothus spinosus Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YAYPTFVTLSOODF-UHFFFAOYSA-N ClNC(CCC)N Chemical compound ClNC(CCC)N YAYPTFVTLSOODF-UHFFFAOYSA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100032900 Dictyostelium discoideum racI gene Proteins 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- CNWYIDPCKBEXIV-UHFFFAOYSA-N [S-2].[Li+].[Al+3].[S-2] Chemical compound [S-2].[Li+].[Al+3].[S-2] CNWYIDPCKBEXIV-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 description 1
- HSJKGGMUJITCBW-UHFFFAOYSA-N beta-hydroxybutyraldehyde Natural products CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-N difluoroacetic acid Chemical compound OC(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- UHKJHMOIRYZSTH-UHFFFAOYSA-N ethyl 2-ethoxypropanoate Chemical compound CCOC(C)C(=O)OCC UHKJHMOIRYZSTH-UHFFFAOYSA-N 0.000 description 1
- FSULVKOFFHWMEU-UHFFFAOYSA-N ethyl acetate;ethyl propanoate Chemical compound CCOC(C)=O.CCOC(=O)CC FSULVKOFFHWMEU-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Chemical group CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- ATHHXGZTWNVVOU-UHFFFAOYSA-N monomethyl-formamide Natural products CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical compound CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005121 nitriding Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000005995 skin dysfunction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910001379 sodium hypophosphite Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical group C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
玖、發明說明: 【發明所屬之技術領域】 特別是 本發明係關於可用作胰島素致敏物(sensitizer PPAR致活劑的新穎♦朵衍生物。 本發明特別關於式丨化合物 〇、〇 R-Ca
(1) 及/、祷藥上可接受的鹽與酯,其中 r1是芳基或雜芳基; r2是氫,烷基或環烷基; 烷氧基或經一至三個ώ素原子取代的烷氧基 民4是氫,烷基或環烷基; 一. Α是氧或疏; 打是1,2或3 ; 及,其中碳原子Ca及Cb間的键是碳碳單键或雙键。 【先前技術】 式I化合物及其醫藥上可接受的鹽與酯是新穎的,且具有 /[貝值的藥理學性質。其為胰島素致敏物(sensitizer),特8 PPAR致活劑。 疋 過氧化物酶體增殖劑活化的受體(PPAR,s)是核激素受體 89200 200413357 總科中的-員,其為調節基因表達的配位體活化的轉錄因 子現已也貝並克隆出其各種次型,包括ppARa,ppA邱(也 %作PPAR3),及pPARy。ρρΑΚγ至少有二種主要異構物。雖 ^ ΡΡΑΙΙγΙ於大多數組織中普遍表達,較&的異構物冲八印 卻幾乎只見於脂肪細胞。相反的,ppARa主要在肝,腎及 。臟内表達。PPAR調節各種身體反應、,包括葡萄糖 穩態,細胞分化,發炎反應及心血管事件。 、糖尿病是病人控制血液内葡萄糖含量的能力受損的疾 病,、因為其部分失去對胰島素作用適當反應的能力。Η型糖 尿病(T2D)也常稱非胰島素依賴型糖尿病(NIDDM),佔所有 已發,國家糖尿病病人的㈣%,患此病的病人的騰臟之 即革罕氏島仍生產胰島i。但標的器官,主要是肌肉,肝 及脂肪組織,對胰島素的刺激有極大抗性,身體非生理性 地產生南量騰島素作為代償。但於此病晚期,由於騰臟衰 ,而使胰島素分泌降低。此外,T2D也是代謝性心血管疾病 欲候。由T2D所致的病態是,例如,姨島素抗性,脂防代謝 障^,高血壓,内皮系統功能不炎性動脈粥樣硬化。 取近對糖尿病的第一線治療包括滴脂-及葡萄糖_飲食及 «。但這-治療也作調整,著疾病的進行,以低血糖 藥物,例如磺醯脲或二甲雙胍治療是必須的。最近已介紹 一類有效的新藥物’其使病人對其本身的月夷島素致敏(騰島 素致敏劑),從而使血葡萄糖及三酸甘油酯含量正常,而放 棄或是減少對外來胰島素的需要。吡格列酮(Act〇sTM)及羅格 列酮(AvandWM)屬於ρρΑΙΙγ激動劑的噻唑烷二酮(tzd)類,是 89200 200413357 已被數國證明為NIDDM的第一批代表物。但此等化合物, 有副作用,包括不常見但很嚴重的對肝臟的毒性(如使用曲 格列酮所見者),並增加人的體重。所以現需一種新的更有 效的藥物治療NIDDM。最近的研究已證明,對PPARoc及ΡΡΑΙΙγ 的同激性(coagonism)會使化合物產生強治療效果,即對葡萄 糖及胰島素量的正常化之外又有改良的脂情況的效果 (Keller and Wahli * Trends Endocrin. Metab. 1993 ; 4-291-296, Mecdonald and Lane : Current Biology Vol. 5頁 618-621 (1995)) o 【發明内容】 本發明新穎化合物,由於其同時結合於PPARoc及PPARy上 並有效地使二者活化,超過了此技藝已知的化合物。所以, 此等化合物兼具ΡΡΑΙΙγ活化的抗血糖效果及PPARoc活化的 抗脂肪代謝障礙效果。因之,使血漿葡萄糖及胰島素降低 (=胰島素致敏化),三酸甘油醋降低及HDL膽固醇升高(=改 進脂肪情沉i )。此外,此類化合物也可降低LDL膽固醇,降 低血壓,並消解發炎性動脈粥樣硬化。由於T2D疾病症狀的 多個方面可由PPARa及ΡΡΑΙΙγ共同激動劑解釋,此等化合物 與此技藝已知的化合物相較,預期會有較好的治療效果。 因之,式I化合物可用於預防及/或治療糖尿病,特別是非 胰島素依賴型糖尿病,高血壓,高脂及膽固醇,動脈粥樣 硬化疾病及代謝病徵。 本發明標的是式I化合物及其前述醫藥上可接受的鹽及 酉旨,及其作為治療活性物質的用途,及製造該等化合物, 中間體,醫藥組合物,含該等化合物,醫藥上可接受的鹽 -9- 89200 200413357 及酯’的藥物的方法,及該等化合 治療疾症,祛卽e + @日及鹽在預防及/或 *、 争疋在預防及/或治療糖尿病,非胰n彳、 型糖尿病,高血壓,高脂及膽㈣ =島素依賴 代謝病徵及特別是在…/❹療二樣硬化疾病及 ^ L 、丨万及飞,口療非胰島素依賴型择尿 娲上的用㉟’及該等化合物,其-舂ά m m ^ 、 在生屋樂物以治 或預防各種疾病,特別是治療及/或預防糖尿病,非騰 =素依賴型糖尿病,高血壓,高脂及膽固_,動脈粥樣硬 化疾病及代謝病徵的藥物上的用途。 發明詳述 、於此說日月+,“垸基,,一詞,不論單獨使用或合併使用, 意謂有1至8個碳原子的直鏈或支鏈的烷基,較佳是有1至6 個碟原子的直鏈或支鏈的垸基,特佳是有以4個碳原子^ 直鏈或支鏈的烷基。直鏈或支鏈的Ci_C8烷基的例是甲基, 乙基’丙基’異丙基’丁基’異丁基,第三_ 丁基,異ς戊 基,異構己基’異構庚基,及異構辛基,較佳是曱基及乙 基,最佳是甲基。 _ “環烷基’’一詞,不論單獨使用或合併使用,意謂有3至8 個碳原子的環烷基環,較佳是有3至6個碳原子的環烷基 環。C3-C8環烷基的例是環丙基,甲基_環丙基,二甲基環丙‘ 基,環丁基,甲基_環丁基,環戍基,甲基_環戍基,環己 基,甲基-環己基,一甲基-環己基,環庚基及環辛基,較 佳是環丙基。 “烷氧基”一詞,不論單獨使用或合併使用,意謂式烷基 -〇,其中“烷基”一詞有前述意義,如甲氧基,乙氧基,正_ •10- 89200 200413357 丙氧基,異丙氧基,正-丁氧基,異丁氧基,第二-丁氧基, 及第三-丁氧基,2-羥基乙氧基,2-甲氧基乙氧基,較佳是 甲氧基及乙氧基,最佳是甲氧基。 “芳基”一詞,不論單獨使用或合併使用,意謂苯基和莕 基,較佳是視需要帶有一或多個取代基的苯基,此等取代 基是獨立選自i素,三氟甲基,胺基,烷基,烷氧基,烷 基羰基,氰基,胺甲醯基,烷氧基胺甲醯基,亞甲基二氧 基’幾基’燒氧基談基’胺基援基^ fe胺基談基’二基 胺基羰基,羥基,以一至三個鹵素原子取代的烷基,硝基 等,如苯基,氟苯基,氯苯基,甲氧基苯基,異丙氧基苯 基,甲基苯基,乙基苯基,異丙基苯基,第三-丁基苯基, 以三氟甲基取代的苯基,以二個甲基取代的苯基,以二個 曱氧基取代的苯基,以二個氟原子取代的苯基,以二個氯 原子取代的苯基,以甲基及氟取代的苯基,或以三個甲氧 基取代的苯基。 “芳烷基”一詞,不論單獨使用或合併使用i意謂前面定 義的燒基或環燒基,其中一或多個,較佳是一個氫原子被 前述芳基所代替。較佳是爷基,以輕基,燒氧基或素取 代的芊基。特佳是芊基。 “胺基”一詞,不論單獨使用或合併使用,意謂經由氮原 子键合的初級,二級或三級胺基,二級胺基基團帶有烷基 或環烷基取代基,三級胺基基團帶有二個相似的或不同的 燒基或環烷基取代基,或此二個氮取代基共同形成一環, 如,例如,-NH2,甲基胺基,乙基胺基,二甲基胺基,二 89200 -11 > 200413357 乙基胺基,甲基_乙基胺基,毗咯啶基或六氫吡啶基等, 較佳疋胺基甲基胺基,及二乙基胺基,特別是初級胺 基。 “齒素”一詞,不論單獨使用或合併使用,意謂氟,氯, 〜或碘,較佳是氟,氣或溴。特佳是氟或氯。 = '或多個’較佳是-或二個獨立選自㈣,烷基’况 “土較哥基_ &基及三氟甲基取代的。特佳是硫苯-2-基。 亩藥上可接受的蹄,,一: ..^ ^ ^ Θ疋扣保有自由態鹼或自由態酸 盥為祕A 仁並不疋生物不需要的。此等鹽是 每播機如鹽酸,氫溴醢 鹽酸,及有機^ H硝酸’磷酸等’較佳是 巧來於機^如乙奴,丙酸,甘醇酸,丙酮酸’oxyHc酸’ 巧不,丙二酸,丁- 、 甲酸,肉桂酸m Γ ’富馬酸,酒石酸,棒權酸,苯 丨J征^,扁桃酸, 酸,水楊酸,N-乙… 乙垸續酸’對-甲苯續 ^ ^ 知丰%胺酸等所構成。此外,此等酸也 不限於,鈉, 氣備。衍生自無機鹼的鹽包括,但 鹽包括,但不m、人、、巧,鎂鹽等。衍生自有機鹼的 Ί IR於,如切 — 、’、 一級及三級胺,經取.代的胺, 2羰基”一詞,不論單獨使用或合併使用,意謂_c(〇)_基團。 “氰基一同,不論單獨使用或合併使用,意謂_cn基團。 口雜万基闷,不論單獨使用或合併使用,意謂孓至1〇_ =的雜環’其含—或多自,較佳是—或二個選自氮、氧及 石-的雖原子’其中以硫為佳。如有必要,可於4或多個碳 :子以i素,垸基,垸氧基’氰基,函垸基及/或三氟甲基 取代。較佳的雜芳基環是峨唆基或苯硫_2_基,其是視需 烷 89200 12 - 200413357 包括天然的經取代的胺,環形胺及鹼性離子交換樹脂,如 異丙基胺,三甲基胺,二乙基胺,三乙基胺,三丙基胺, 乙醇胺,賴胺酸,精胺酸,N-乙基六氫吡啶,六氫吡啶, 聚胺樹脂等。式I化合物也可以兩性離子形式存在。特佳的 fe'樂上可接受的鹽是鋼鹽。
式I化合物也可是溶劑合物,如水合物。溶劑化可在製造 過私中形成或發生於原本是無水式合物的收濕性(水合 化)。醫藥上可接受的鹽一詞也包括生理上可接受的溶 ^ 〇 "口
w樂上可接受的酯”—詞意謂通式〗化合物可於官能』 團上發生衍化生成能在活體内再轉化成母化合物的2 ^ 物:此等化合物的例包括生理上可接受的及代謝上易❼ 酯衍生物’如甲氧基甲基酯,甲基硫基甲基酯及新戊醃! 甲基酿。其他醫藥上可接受的酯是垸基,幾基燒基’㈣ :烷基’胺基烷基,單-或二-烷基_胺基烷基,嗎福林二 土,口比嘻呢基垸基,六氫峨症基垸基,六氫咐啡基垸基’ 烷基六氫吡畊基燒基,及芳烷基酯。 土 ::卜:任何生理上可接受的通式⑴化合物的相當物,· 凰;代謝的醋,其可於活體内生成通式⑴母化合物, 屬於本發明範圍。 _Ί . &物。例如美國專利4,598,〇89號所揭示的奥 :他Π:及里卜斯他丁 (lipstatin)即為有效的脂物 ’ 丁為天然的微生物產物,奥利司他為里卜 89200 -13 - 200413357 他丁虱化後的結果。其他脂抑制劑包括一般稱作潘可利新 (pandlcms)的化合物。潘可利新為奥利司他類似物(Mutoh et 吐1994)。“脂酶抑制劑,,一詞也指結合聚合物的脂酶抑制 劑,例如國際專利申請案w〇99/34786 (㈤㈣心職__ ㈣所述者。此等聚合物的特點是其已經—或多個抑制脂酶 的f團所取代。“脂酶抑制劑,,一詞也包括醫藥上可接受的 此等化合物的鹽。“脂酶抑制劑,,一詞較佳是指奥利司他。 奥利司他是已知的用於控制肥胖及高血脂的化合物。見 1986年7月1日頒發的美國專利4,598,〇89號,此專利也揭示奥 =司他的製法’以及美國專利6,_,996號,其揭示適宜的醫 藥組合物。其他適宜的醫藥組合物見國際專利申請案 WO00/09122及WO00/09123號。奥利司他其他的製法揭示= 歐洲專利申請案 185,359,189,577,443,449及 524,495號。 與利司他可以每天60至720毫克分成二至三次經口給 予。脂酶抑制劑較佳是每天18〇至36〇毫克,最佳是36〇毫克 給予病主,較佳是每天分成二次,特佳是分成三次給予。 病主較佳是肥胖的人,即體重指數25或更大的人。脂酶抑 制劑一般較佳是在攝取含有脂肪的飲食約一或二小時内給 予。一般而言,上述脂酶抑制劑的給予較佳是用於治療有 肥胖家族史的且體重指數為25或更大的人。 奥利司他可以習用的口服組合物給予人,如錠,塗覆的 鍵,硬及軟明膠膠囊,乳液或懸浮液。可用於錠,塗覆的 錠’糖衣錠,及硬明膠膠囊的戴劑的例是乳糖,其他的糖 及糖醇如山梨糖醇,甘露糖醇,麥芽糖糊精或其他填充劑· 89200 -14- 200413357 月桂基硫酸納,呵96’或吐溫 叔粉甘醇酸鋼,玉米澱粉或其 朋u如 交鏈聚維酮;㈣;硬脂酸…等:;/如聚維酮’ I j疋 植物油,4t,半固體及液體多元醇等。 :醫藥製劑還可含防腐齊彳,助溶劑’ :Γ、:Γ劑,㈣,靖味劑,改變渗透壓的鹽 人 杬乳化劑。也可含其他治療上有價值的物 的方=配物可製成單位劑形,並可以任何此技藝已知 :法t備。較佳是奥利司他是根據美國專利6,。。4,99 1門尸β π給予。 物較佳是式!化合物及其醫藥上可接受的鹽,特収幻化合 至三個取代 ,鹵素,及 其他較佳的式I化合物,其中R1是苯基或經一 基取代的苯基,此等取代基選自烷氧基,烷基 一至三個画素取代的烷基。特佳的是這樣的式I化合物,其 中R】是苯基或經一至二個取代基取代的苯基,此等取代基 墣自烷氧基,烷基,卣素,及一至三個卣素取代的烷基。 甚佳的式I化合物,其中Rl是苯基,二甲氧基苯基,異丙 基-苯基,氟-苯基,氯-苯基,甲基-苯基,三氟甲基-苯基, 甲基-氟-苯基,或異丙氧基-苯基。 本發明其他較佳具體實施例是式I化合物,其中R2是氫, 甲基或乙基。特佳是這樣的化合物,其中R2是氫或甲基。 甚佳是這樣的化合物,其中R2是甲基。 也佳是這樣的化合物,其中R3是甲乳基或乙氧基。特佳 89200 -15 - 是乙氧基。 本發明另一較佳方面是式丨化合 0 物,:Μ:φρ4σ 与 又車父佳的是這樣的式I化合物,复+ a 疋里 是碳-碳雙鍵。此等化合物有如:CM碳原予間的鍵 V〇 '"式Ia R34a
• I ㈣ /、中R至R4,八及n之定義如#逑。 特佳的是這樣的式][化合物,其 碳-碳單鍵。此等化合物有如 & ♦、間的鍵是
R3-Ca D-
R丨 cu (lb) R2 其中R1至R4,A及n之定義如前迷。 較佳的是這樣的式I化合物,其中。特佳的是這名 的式I化合物,其中η是1或3。尤佳的是這樣的式t化合物 89200 卉肀η是i。 樣==這式1化合物,其中Α是硫。特佳的是這 物其中A是氧。 體,對::二含:個:對稱中心,並可以光學上的純對晚 異構物’非鏡像立」^旋物,光學上的純非鏡像立體 旋物或非鏡像立二=物,非鏡像立體異構外消 學活性形式可"^合_式存在。此等光 不對Β 列如’外消旋物解析,藉不對稱合成或 得,層分析(以對掌性吸附劑或洗離劑作色層分析)取 :不對稱碳原子,,一詞意謂有四個不同取代基的碳原子。 艮 Cahn-Ingold_Prel〇g_c〇nventi〇n,不對稱碟原子可 “S”構形。 4 較佳是對掌性式化合物,
RkG·
〇、〇 ⑽ 其中R1至R4,A及η之定義如前述,不對#山 1對%碳原子Ca是R構形。 特佳是對掌性式(Id)化合物, 89200 17 200413357
其中R1至R4, A及η之定義如前述,不對稱碳原子Ca是S構形 〇 較佳式(I)化合物的例是 rac-3-{l-[2-(3,5-二甲氧基-苯基)-5-甲基j号唑-4-基甲 基]-1H-㈤p朵-4-基}-2-乙氧基丙酸, ; rac-2-乙氧基- 3- {l-[2-(4-異丙基-冬基)-5-甲基-^亏。坐-4-基甲 基]-1H-吲哚-4-基卜丙酸; rac-2-乙氧基-3-{l-[3-(5-甲基-2-苯基-崎唑-4-基)丙基]-1H -啕哚-4-基卜丙酸; rac-2-乙氧基-3-{ 1-[2-(5-甲基-2-苯基-口号唑-4-基)乙基]-1H-啕哚-4_基}-丙酸; 1^〇2-乙氧基-3-[1-(5-甲基-2-苯基-呤唑-4-基甲基)-111-4丨哚 -4-基]-丙酸; rac-2-乙氧(基-3-{l-[2-(2-鼠-私基)-5-甲基-口号口坐-4-基甲基] -1H-Η丨哚-4-基}-丙酸; 1^〇3-{1-[2-(2-氯-苯基)-5-甲基-哼唑-4-基甲基]-1士4丨哚-4-基}•乙氧基-丙酸, 1^-2-乙氧基-3-[1-(5-甲基-2-〇-甲苯基^号唑-4-基甲基)-]^-啕哚-4-基]-丙酸; · 89200 -18 - 200413357 rac-3-{ l-[2-(3-氣-苯基)-5-甲基j咢唑-4-基甲基]-1H-啕哚-4-基卜乙氧基-丙酸; rac-2-乙氧基-3-{1-[5-甲基-2-(4-三氟甲基-苯基)-呤唑-4-基 甲基]-1H-W哚-4-基}-丙酸; rac- 2-乙氧基-3-{l-[2-(4-鼠-3-甲基-苯基)-5-甲基-口号。坐-4 -基 甲基]-1H-啕哚-4-基卜丙酸; r ac - 2-乙氧基-3-{l-[2-(4-異丙氧基-苯基)-5-甲基-p号。坐-4 -基 甲基]-1H-啕哚-4-基卜丙酸; rac-2-乙氧基- 3- {l-[2-(4-異丙基-苯基)-禮_。坐-4-基甲基]-1H-啕哚-4-基卜丙酸。 特佳式(I)化合物的例是 rac-3-{ 1-[2-(3,5-二甲氧基-本基)-5-甲基-p亏口坐-4 -基甲 基]-1H-啕哚-4-基}-2-乙氧基丙酸; rac-2-乙氧1基-3-{1-[3-(5-甲基-2-苯基-口号口坐-4-基)丙基]-1Η_ ㈤哚-4-基卜丙酸;及 rac-2-乙氧基-3-{1-[2-(4-氟-3-甲基-苯基)-5-甲基-呤唑-4-基 甲基]-1H-啕哚-4-基卜丙酸。 式I化合物的製造方法是本發明目的。 *以下製造方法中所用取代基及指數,除非另有說明,具 上述意義。 通式⑴化合物,其中R1至R4,A及η之定義如前述,可根 據方案I製備:
方案I -19- 89200 200413357
(2) R=燒基,芳基或芳虎基,較佳是乙基
(lb) (la) 4-甲醯基·吲哚(1)可與 Wittig鹽(Bach,Karen Κ·; El-Seedi, HeshamR. ; Jensen,Henrik ; Nielsen,Helene B. ; Thomsen,lb ; Xorssell,Kurt B.G ; Tetrahedron (1994) ’ 50(25),7543-56)如氯 化(1,2-二乙氧基-2-氧乙基)-三苯基-膦或氮化(1-曱氧基-2-苄基氧基-氧乙基)·三苯基-膦在溶劑如異丙醇,二氯甲烷或 四氧吱喃或其混合物内在有驗如碳酸钾或四甲基胍之存在 下,於較佳是〇°C至溶劑回流溫度反應’製得丙稀酸酯(2), 為E及/或Z異構物。 (2)之以雜環(3)烷基化可於溶劑如N,N•二甲基甲醯胺内 在有鹼如氫化鈉或第三-丁酸鉀之存在下,於較佳是0°C至 -20- 89200 200413357 室的溫度間進行,繼之將酯官能水解,較佳是以氫氧化 I里於如二。亏燒之溶劑内於較佳是〇。〇至室溫的溫度間進 行。或者是,雜環(3)之烷基化可用K〇H於DMSO内於0°C至 80 C較佳是22°C進行;使用上述條件,並於原位水解成對 應的fei ’以一步驟製得丙缔酸(Ia)。 將(la)於飽/碳上於如甲醇,乙醇,二氯甲烷或四氫呋喃 或其混合物之溶劑内行氫化,製得吲哚丙酸(Ib)。 或者是,通式(Ib)化合物,其中R1至R4,A&n之定義如前 述,可根據方案11製備:
方案II
(3) 鹵素,CH3S〇3
COOH COOR
89200 -21 - 200413357 根據方案II (lb)之另一製備方法,較佳是用於R3及R4為固定 的而R1,R2及A是變化的情形,其反應與方案I所述相同。 除方案I及II所述工序外,通式(lb)化合物,特別是R3改變 的化合物,可用方案III製備:
方案III
Η
+ Prot. ⑴ ⑹ COOR 鹵素,ch3s〇3 x
89200
(lb) (5) -22- 200413357 可用於啕哚氮基團帶有適宜的保護基(pr〇t),例如2_三甲 基甲夕烷基乙氧基甲基(SEM)基團或苯磺醯基的甲醯基口弓丨 木(6)與^氧基·乙㉟的稀醇醋(較佳是於-78t:於如四氫吱喃 ,冷^内以鹼如二異丙基醯胺鋰製備)於低溫反應,製得醛 醇化合物⑺,為非鏡像立體異構外消旋物混合物。以不同 勺a成込栓視所用保謾基而定,可將化合物(7)轉化成啕 木丙酸(4)。如果用苯續酸基作為♦果保護基,則用如下二 步驟工序.·. 〇用對-甲苯磺酸在類如苯之溶劑内於回流處理 、去K U)用鍰在甲醇内於回流反應同時減少雙鍵並除去 保^基。如果用21基甲碎垸基.乙氧基甲基(sem)作為旁果 呆叹基J用如下五步驟工序:丨)用甲烷磺醯氯在類如二氯 J烷艾洛劑内處理,繼之以例如丨,8-二氮雙環[5·4•…十一· 、希’5)在頒如四氫呋喃之溶劑内於高溫處理,得不飽和酯 、、—物為E及/或z兴構物混合物;丨丨)用例如鈀/碳在如乙醇 内將又鍵氧化’ lu)以標準條件使醋官能息化;⑺用例 ^氟化四丁基銨(四氫咬喃内之溶液)於如二甲基甲酸 旧内之,合釗中在有伸乙基二胺之存在下較佳於別。〇至⑽艺 又除去保產,V)用例如甲基碘,碳酸氫納在N,N-二甲基甲 ^月文内重S旨化。用雜環(3)與化合物(4)縮合,# §旨化合物 (5\,繼乏可如方案1及11所述皂化成化合物(Ig)。 歸同手性酸(lb)可藉製成光學上的純或光學上濃縮的中間 化(j如用脂辦使外消旋酷(4)解析,分離後再將解析的酸酯 )敗備,再進一步將光學上的純或光學上濃縮的酯(4)轉化 、光學上的純或光學上濃縮的酸(lb)。或者是,將外消旋或 89200 -23 > 200413357 光學上濃縮的酸(ib)以此技藝已知方法分成其對映體,如用 光學上的純胺,如(幻或^)·1·苯基_乙基胺,(R)或(S)-l-莕 -1-基-乙基胺’番木鱉鹼,喹嚀或喹嚀定結晶非鏡像立體異 構鹽刀離對映體,或是藉特異色層分析法用對掌吸附劑或 對掌洗離劑分離對映體。 4-甲酿基-吲哚(丨)是已知的或可以此技藝已知方法合 成’例如用對應的4-溴-或4-碘-吲哚;丨)以氰化酮⑴於喹啉 内於200 C至270 C溫度間處理(比較Liebigs Ann. Chem. 1975, 160-194) ’再將生成的腈用次亞磷酸鈉及阮尼鎳,較佳是於 水、酷酸及吡啶之混合物内於室溫至6〇。〇溫度遇原[比較
Helvetica Chimica Acta (1968) 51,1616-1628]或 ii)以對應的 4-溴 一或4-蛾4丨嗓’其可視需要於吲哚氮原子上帶有保護基,用 坑基鍾試劑,例如正-丁基鋰,於類如四氫呋喃之溶劑内於 -78 C處理,繼之用Ν,Ν-二甲基甲醯胺或义甲醯基六氫.吡啶 處理。 視需要於引哚氮原子上帶有保護基的‘溴-或4-碘-啕哚 是已知的,或此技藝已知方法合成;4_溴-或各碘_ 4丨哚的可 月匕的 & 成方法見 Chemistry-A European Journal (2002), 8(9)’ 2034-2046及 Tetrahedron Letters (2001),42(6),983-985。 式(3)起始化合物,其中a是氧,n是1或2,可根據方案IV 製得。
方案IV
(1a) (2a) (3a) 〇 Η 89200 -24 - 200413357 b
醛(la)是商業上可購得的,於文獻中也有敘述。根據文獻 工序(Goto,Y. ; Yamazaki,M. ; Hamana,M. ; Chem 〇harm Bull (1971),19,2050)在有強酸,典型的是HC1之存在下,於極 性溶劑如Ac〇H内將其與二酮-單肟(2a)縮合,生成呤唑-N-氧化物(3a)(步驟a)。繼之用P〇C13於二氯甲烷内在回流下處 理,得對應的初級氯化物(4a)(Goto, Y. ; Yamazaki,M.; Hamana, Μ. ; Chem Pharm Bull (1971),19,2050,步驟 b)。此等中間 體可原樣使用或根據已知方法轉化成對應的醇活活化的 醇,如甲烷磺酸鹽或甲苯磺酸鹽,或是轉化成溴化物或碘 化物,或最終經由與NaCNR SN2-反應,經腈(5a),’充分水解 -25 - 89200 200413357 (步驟d)及還原(步驟e),例如用硼烷在四氫呋喃内反應,生 成結構單元(7a)。最後可將醇(7a)轉化成式(3)化合物,例如 用甲烷磺醯氯於二氯甲烷内在有鹼如三乙基胺之存在下較 佳是於-20°C至室溫溫度處理,或與四氯化碳或四溴化碳及 三苯基膦在溶劑如四氫呋喃内較佳於室溫至溶劑回流溫度 反應;這樣生產出的式(3)化合物分別為甲烷磺酸鹽,氯化 物或溴化物。 R2為氫的4-氯曱基-2-芳基或2-雜芳基-崎唑(4a)較佳是用 對應的芳基或雜芳基羧醯胺及1,3-二氯丙酮製餚,如Bioorg. Med. Chem. Lett· (2000),10(17),2041-2044所述。 式(3)起始化合物,其中A是氧及n是3,可根據例如方案V 製得。
方案V
Η +
〇
(1b)
C〇〇H 〇 R1—^ κ (4b)
d 89200 -26- 200413357 0^R r1~Jl e 〇YR2 nJS (5b)、 ㈣Uh N-醯基-甘胺酸酯(11^是商業上可購得的,已知的,或可以 標準N-醯化製備的。單埽丙基酿(2b)可藉將(1_ 核鹼如LlHMDS於質子惰性溶劑如THF内於—78t;行去質子 化’再用烯丙基溴處理有選擇性地生成c_烷基化的產物 (2b)(步驟a)。以標準水解生成中間體酸(3叫步驟然後根 據已知的文獻工序(;· Hed. Chem· (1996),%,彻7)轉化成化 e物(4b)(步|4a c)。用二氟醋酸及三氟醋酸哥作試劑使。号峻 行I封閉生成關键中間體(5b)(步驟d),最後行硼氫化反應 生成標的醇(6b),例如用於THF内反應,再以h2〇2及
NaOH行氧化收取(步驟e)。最後,例如用甲烷磺醯氯在二氯 甲;fe内在有驗如三乙基胺之存在下較佳於·机至室溫溫 度處理,或與四氯化碳或四溴化碳及三苯基膦在溶劑如四 虱呋喃内較佳是於室溫及溶劑回流溫度間反應,轉化成式 ()a物,這樣生成的式(3)化合物分別為甲垸福酸錄,畜 化物或溴化物。 〃 | 氣 、()I七化合物,其中A是硫及η是1,可根據如安 VI製得。 表
方案VI
νη2 (1c)
a (3c) 89200 -27- 200413357
Cl/Rr
v (4c) R2
Cl (5c) (6c) 硫酸胺(lc)是已知的,或可、 、 飞了以此技藝已知万万法製得,例如 、對應的竣醯胺用五硫化鱗或用Lawess〇n氏試劑[2,4·雙(心 :氧ί苯基二硫雜久4·二膦元'4-二硫化物]於:劑 曱。苯内於較佳是60 C至溶劑回流溫度處理製備。硫酿胺 (jc)可與,二氣丙酮於溶劑如丙酮或乙腈内於室溫至溶 1回机溫度縮合,再用強酸如濃硫酸,較佳是於室溫處理 (v馼a)。或者是,將硫胺(lc)與心溴或心氯酮(如)於溶劑 乙醇内,車父佳是於回泥溫度縮合,生成於4_位帶有甲基 保護基的芳基塞唑(5c)(步驟b)[比較歐洲專利申請案(1987) EP 207453 A2]。此等芳基嘍峻(⑷以N_氯丁二醯胺於溶劑如 乙腈内,較佳是於回流溫度處理,得氯甲基化合物(6c)(步 釭 c)[比較 PCT Int_ Αρρ· (2001),w〇 0 1 1 9805 A1]。 式(3)起始化合物,其中A是硫及η是2或3,可根.據例如方 89200 -28- 200413357
案VII製得。 方案VII
(1d) (2d) (3d) b
將硫醯胺(Id)與適宜的雙-親電子試劑,例如审 产 τ基‘溴-或 4-氣-3-氧-烷酸酯(2d),較佳是於溶劑如甲苯内於*、w/ 回 >皿(例如 回流溫度)縮合,得於4-位帶有乙酸酯官能基的喧唆(3d)( + 驟 a)[比較 PCT Int. Appl· (1997),WO97/31907 A1]。心漠 一3 氧 坑酸S旨(2d)是已知的或是可以此技藝已知方法製得的[比转 PCT Int. Appl. (2001),w〇〇1/792〇2 A1]。嘍唑(3d)可用例如^ 化鋰鋁還原成嘍唑(4d)(步驟b)。有需要時,側鏈之延長可 以標準方法完A ’例如將_官能基轉變成離去&,例如甲 磺酸醋’#以氰化物處理,惠化,還原,製得心位有羥基 丙土 g月匕基的口塞坐(5d)(步驟c)。最後可將醇㈣)及⑼)—柄 準工序活化成甲績酸酉旨或甲笨續酸酿。 … -89200 '29- 200413357 式I化合物之轉化成醫藥上可接 ^ ^ |」猎將此化合妝 以典機鉍如氫自素酸,如鹽酸或氫 广丄 穴^ 硫酸,硝酸,礓 酸,寺或以有機酸例如乙酸,檸樣酸,馬來酸, 酒石酸,甲料酸,或對·甲苯錢,等處理進行 叛酸鹽也可用式ί化合物以生理上相容㈣如氫m 鉀或三級胺如三乙基胺處理製備。 " 式I化合物之轉化成醫藥上可接受的g旨或醯胺可藉將分 子内的1宜的胺基或輕基以賴如乙酸以縮合劑如苯并三 唑小基氧基參(二甲基胺基)鳞六氟磷酸鹽(B〇p)或N,队二 環己基碳化二亞醯胺(DCCI)處理,生成羧酸酿或羧酸醯胺。 式I化合物之轉化成醫藥上可接受的酯,較佳是,藉將式 (I)化合物在有縮合試劑如苯并***小基氧基參(二曱基胺 基)鱗/、氟磷酸鹽(BOP)或N,N-二環己基碳化二亞醯胺(DCCI) 及4-二甲基胺基-吡啶之存在下以對應的醇於溶劑如凡咚二 甲基甲酿胺内根據已知方法處理完成。 更佳的疋製備式I化合物的方法,其包括如下反應之一: a)以下式化合物
在有下式之化合物 89200 -30- (8) 200413357 x
(3) 其中R1至R4,A及η之定義如前述’ X是鹵素或CH3S〇3 ’反是 烷基,芳基或芳烷基,及其中ca&cb硬原子間的键是碳石炭 單鍵或雙键之存在下反應; b)將下式化合物氫化
〇
其中R至R4,A及η之定義如前述。 (la) 較佳的中間體是: 乙氧基-3_(1沁啕, raC>2-乙氧基*Ί(1Η^丨哚-4-基)丙酸乙基酯。 、t前所述’本發明式⑴化合物可用作藥曰物以治療及/或 ㈣PPARa& /或ΡΡΑΚγ激動劑調節 糖尿病’特別是非胰島素依賴型糖尿/,,;厂“例 高膽固醇’動脈粥樣硬化,代謝病徵内-血於:局脂 凝血態’脂肪代謝障礙,多病:皮功能障礙, 病’發炎性腸疾病,結腸 <政’發炎疾病(如牙 人胰臟炎,肝膽汁阻塞/纖維化 89200 -31 - 200413357 以及有發炎因素的疾病如 改善)及增生性疾病(癌如月匕//1 士氏病或^知功能受損/ 臟癌,及乳癌)。較佳曰用曰“田、’〜腸癌’***癌,胰 型糠尿病的藥物。疋/口療及/或預防非騰島素依賴
上逑用作治療活性物I 的。較佳是用作箱、、、令、式1化a物是本發明又一標 血壓,-r及”广及/或治療非胰島素依賴型糖尿病,高 是非二醇,動脈粥樣硬化,代謝病徵,特佳 疋非胰島素依賴型糖尿病,的治療活性物質。 及A:發Γ㈣是供製備藥物以預防及/或治療由 ΐ或PPA_動劑調節的疾病上述化合物,較佳是供生產 ::以預防及/或治療糖尿病,非姨島素依賴型糖尿病,高 e ^知動脈粥揼硬化,代謝病徵,特佳 疋非騰島素依賴型糖尿病。 痊:::又一標的是醫藥組合物,其含上述式I化合物及治 二、、Λ::]“生的戴劑。本發明又-標的是醫藥組合物,其尚 、人有效里的月曰抑制削,特別是此脂酶抑制劑為奥利司 他0 口本發明的標的也是上述化合物在製成藥物的用途,特別 疋供治療及/或預防由冲心及/或ΡΡΑΚγ激動劑調節的疾 較佳是糖尿病,非胰島素依賴型糖尿病,高血壓,高 脂及高膽固醇’動脈粥樣硬化及病或代謝病徵,並特佳是 非胰島素依賴型糖尿病。 本發明另—標的是使用式1化合物製造藥物供治療及/或 預防病人由PPARa及/或pPARy激動劑調節的疾病,.此病人也 89200 -32- 200413357 接受脂酶抑制劑治療。較佳的上述用途是,其中脂酶抑制 劑是奥利司他。特佳是上述治療/及或預防疾病上的用途, 其中疾病是糖尿病,非胰島素依賴型糖尿病,高血壓,高 脂及高膽固醇,動脈粥樣硬化,代謝病徵,特佳是非胰島 素依賴型糖尿病。 本發明又一標的包括以上述製法製造的化合物。 本發明又一標的是藉給予有效量的式I化合物治療及/或 預防由PPARoc及/或ΡΡΑΙΙγ激動劑調節的疾病,較佳是糖尿 病,非胰島素依賴型糖尿病,高血壓,高脂及高膽固醇, 動脈粥樣硬化及病或代謝病徵,並特佳是非胰島素依賴型 糖尿病的方法。本發明又一標的是上述方法,其尚包括給 予人治療有效量的脂酶抑制劑,特別是其中脂酶抑制劑為 奥利司他。以上述方法同時、分別或相繼給予也是本發明 標的。 鑑定工序 下述試驗可用以測定式I化合物的活性。 進行艦定的資訊背景見於:Nichols JS et al.,“Development of as cintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain” ,(1998) Anal. Biochem. 257:112-119 。 由人脂肪組繳及鼠肝cRNA藉RT-PCR取得供人PPARoc及鼠 ΡΡΑΙΙγ用的全長cDNA克隆,克隆成質粒載體,並以DHA排序 證實。建成細菌及哺乳動物表達戴體以生產融合於PPARY (約174至476)及PPARoc (約167至469)配位體結合i(LBD)的 -33 - 89200 200413357 穀光甘肽-s-轉移酶(GST)及Gal4 DNA結合域蛋白。這樣作 時,將編碼LBD的克隆排序部分以PCR由全成克隆放大,然 後再次克隆(subdoned)成質粒載體。終克隆用DNA排序分析 確證。 以標準方法用大腸桿菌株BL21 (pLysS)細胞完成GST-LBD 融合蛋白的誘導,表達及純化(參考:Current Protocols in Molecular Biology,Wiley Press,edited by Ausubel et al·) 〇 放射配位體結合鑑定 以 TKE10 (10 mM Tris-HC卜 pH 8, 50 mM KC1,2 mM EDTA, 〇·1毫克/毫升無脂肪酸BSA及10 mM DTT)鑑定PPARoc受體結 合。於每一 96凹内將相當於2.4微克GST-PPARoc-LBD融合蛋 白及放射配位體,例如40000衰變/分的2(S)-(2-苯甲醯基-苯 基胺基)-3-{4-[1,1-二氚-2-(5-曱基-2-苯基-嘮唑-4-基)-乙氧 基]-苯基卜丙酸,以100微升容積於室溫培養2小時。以固體 相分離用裝有80微升SG25的Multiscreen碟(Millipore)按製造 廠說明分開已結合的配位體與未結合的配位體。 以 TKE50 (50 mM Tds-HC卜 pH 8,50 mM KC卜 2 mM EDTA, 〇_1毫克/毫升無脂肪酸BSA及10 mM DTT)鑑定PPARa受體結 合。於每一 96凹反應,在搖動下將140毫微克當量的GST-ΡΡΑΙΙγ-LBD融合蛋白結合於1〇微克SPA珠(Pharmacia Amersham)上,終容積50微升。所得泥樣物質於室溫培養1 小時,以1300 g離心2分鐘。取出含未結合蛋白的上清液, 將含受體塗覆珠的半乾小丸溶於50微升TKE内。作放射配位 體結合時,加例如50微升10000衰變/分的2(S)-(2-^甲醯基- -34- 89200 200413357 苯基胺基)-3-{4-[1,卜二氚-2-(5-甲基-2-苯基j咢唑-4-基)-乙 氧基]-苯基卜丙酸,此反應物於室溫培養1小時,行閃爍近 似質計數。所有結合鑑定都於96凹碟内完成,以Packard TopCounl^ OptiPlates (Packard)測定結合蛋白量。在有 ΙΟ·4 Μ 未標記的化合物之存在下測定非特異結合。在1(Γ1() Μ至10_4 Μ濃度範圍内作成三份劑量反應曲線。 螢光素酶轉錄受體基因鑑定 將幼鼠腎細胞(ΒΗΚ21 ATCC CCL10)於37°C種於95%〇2:5% C〇2氣下含10% FBS的DMEM培養基内。將細胞種於6凹的碟 内,密度10細胞/凹,然後以pFA-PPARY-LBD或 pFA-PPARoc-LBD表達質粒加pFR-luc受體質粒及作為正常化 對照的編碼可分泌形式的鹼性磷酸酶(SEAP)的表達質粒作 成批轉染。轉染係以Fugene 6試劑(Roche Molecular Biochemicals)根據所附建議完成。轉染6小時後,以胰酶消 化收穫細胞,以104細胞/凹密度種於96凹的碟内。任細胞附 著24小時俊,取出培養基,代之以100微升無驗紅的介質, 内含試驗物質或對照配位體(終濃度0.1% DMSO)。在以物質 培養細胞24小時後,收取50微升上清液,分析SEAP活性 (Roche Molecular Biochemicals)。將其餘上清液傾出,每凹内 加50微升PBS,再加一容積勞光素酶彳亙定光試劑(Luciferase Constant-Light Reagent)(Roche Molecular Biochemicals)融解細 胞,開始勞光素酶反應。以Packard TopCount測定SEAP及勞 光素酶的發光。將螢光素酶活性正常化至SEAP對照,在有 試驗物質的存在下以在無物質下培養的細胞的倍_數活性表 35 - 89200 200413357 達。以 XLfit程式(ID Business Ltd· UK)計算 EC50值。 本發明化合物之IC5〇值對PPARoc及ΡΡΑΙΙγ低於50 μΜ。較佳 化合物之IC5G值對PPARa及ΡΡΑΙΙγ低於10 μΜ。更佳低於3500 ηΜ。極佳化合物之IC5〇值對PPARoc及ΡΡΑΙΙγ低於1000 ηΜ。 本發明化合物之EC50值對PPARa及ΡΡΑΙΙγ低於50 μΜ。較佳 化合物之EC50值低於10 μΜ。更佳化合物對之EC50值對 PPARoc及ΡΡΑΙΙγ低於3500 ηΜ。極佳化合物之EC50值對PPARoc 及 ΡΡΑΙΙγ低於 1000 ηΜ。 下表示某些選出的本發明化合物及此技藝已知化合物 (如:Rosiglitazone,Drugs 1999,Vol 57(6),921-930)之測出值。 PPARa IC5〇 (μΜ) PPARa IC50 (μΜ) ΡΡΑΙΙγ IC5〇 (μΜ) 實例1 0.068 0.008 0.007 實例2 0.053 0.20 0.093 實例3 0.27 0.19 0.090 實例10 1.4 0.044 0.14 羅格列酮 1090 nmol/1 無活性 405 nmol/1 式I化合物及其醫藥上可接受的鹽與酯可用作藥物,例如 以其供經腸非經腸或局部給予的醫藥製劑。其可,例如, 作經口給予,例如以錠,塗覆的錠,糖衣錠,硬及軟明膠 膠囊,溶液,乳液或懸浮液的形式給予,作直腸給予,例 如以塞劑的形式,作非經腸給予,例如以注射溶液或輸液 溶液的形式,作局部給予,例如以膏,霜或油的形式給予。 醫藥製劑的生產可以精於此技藝者所熟知的方式進行, 將所需式I化合物或其醫藥上可接受的鹽與適宜的無毒 的、惰性的、治療上相容的固體或液體載劑,必要時再加 醫藥佐劑,製成醫藥給予形式。 ., 此類載劑物料不僅是無機載劑物枓,也是有機載劑物 -36· 89200 200413357 料。所 酸或其 劑物科 蠟,脂 軟明膠 物料是 所用適 及植物 化油, 適宜的 液體蠟 維素衍 以,如乳糖,玉米澱粉或其衍生物,、、典 鹽可用作錠,塗覆的錠,捧衣如,硬脂 ^ 衣1及硬明膠膠囊的番 。、敕明膠膠囊的適宜的載劑物料是,例如 ^載 肪及半固體及液體多元醇(但視活性劑油, 膠囊可不需載劑)。生產溶液及糖衆用的適宜:二; :例如’水’多元醇’蔗糖’轉化糖等 、 宜的載劑物料是,例如,水,醇,夕—、 岭收 ;、 咚夕兀醇,甘油, 油。塞劑的適宜的載劑物料是,例如 天然的或硬 虫風,脂肪’及半固體或液體多元醇。局部製 載劑物料是甘油酯,半合成及合成甘油酯,氫化油, ’液體石躐,液體脂肪醇,固醇,窀 一 生物。 〜乙-酵,及纖 一般的安定劑,防腐劑,濕潤及乳化劑,均質增進劑, 矯味劑,改變滲透壓的鹽,緩衝劑,助溶劑,增^劑^及 遮掩劑與抗氧化劑可認作是醫藥佐劑。 式I化合物的劑量可視要控制的疾病,病人年齡及個別情 況以及給予方式而作大幅度變化,自然需適用於每一病= 的個別需求。就成年病人言,可考慮每日劑量約01毫克至 約1000毫克,特別是約〇1毫克至約1〇〇毫克。更佳是成人每 曰約1毫克制約1000毫克,特別是約!毫克至約1〇〇毫克。視 所用劑量’較方便是將每日劑量分成數劑量單位給予。 醫藥製劑一般含約0.05-500毫克,特別是0.5-500毫克,較 佳是〇·5-1〇〇毫克式^匕合物。 下列實例用以說明更詳細地本發明。不能以任何方式視 為是對範圍的限制。 ·’ 89200 -37- 200413357 【實施方式】 之製備 丨隻^基v丙醢乙基酯 a) (Z)-2-乙氧基-3-(1Η-吲哚-‘基)_丙烯酸乙基酯 於3 5.01克(81.6毫莫耳)氯化(丨,二乙氧基-2-氧乙基)三苯 基膦於200毫升二氯甲烷内之溶液中於〇。〇加11〇1毫升工 毫莫耳)四甲基胍,將此混合物加溫至22。〇。此混合物用 克(54.4¾莫耳)4-甲醯基-吲哚處理,於4〇^繼續攪拌16小 時。此混合物再以1〇.〇克(23.3毫莫耳)Wittig鹽及8.0毫升(24.0 晕莫耳)四甲基胍處理,於4〇它繼續攪拌24小時。此時反應 已芫全。將反應混合物倒入碎冰内,然後用Meci2萃取。合 併足有機相用水洗,於MgS〇4上乾燥,過濾及蒸發。殘餘物 於二氧化矽上作色層分析(正-庚烷/Ac〇Et,95:5至4:1),得 15 · 12克標題化合物為淺黃色固體。 MS : 259.1 (M+)。 b) rac-2-乙氧基_3·(1Η-吲哚_4_基)-丙酸乙基酯 將15.0克(Ζ)-2-乙氧基_3-( 1H-W哚-4-基)-丙晞酸乙基酯於 25〇毫升EtOH内的懸浮液及3 〇8克Pd/C於2yc氫化2小時,然 後停止氫化。將懸浮液過濾,濾過物蒸發,殘餘物於二氧 化石夕上作色層分析(洗離劑:己烷及醋酸乙酯梯度),得12 28 克標題化合物,為淺棕色油體。 MS : 279.2 (M+NH4)+。 終化合物之製備 實例1 89200 -38 - 200413357 rac-3- U 甲氧某-菜某 基 _ 口号口坐·4·某甲 m η - 朵二4 -基」:.乙氣某-丙酸乙 將0.048克(1.10¾莫耳)氫化鈉(55%,於礦物油内)於5。〇在 氬氣下一次加於攪拌的0.261克(1.00毫莫耳)ra(>2-乙氧基 -3-(lH-W哚-4-基)-丙酸乙基醋及〇.321克(12〇毫莫耳)‘氫 甲基^-^乂一甲氧基-苯基^^-甲基-呤唑於^力毫升队义二 甲基甲醯胺内的溶液中。將此反應混合物加熱至室溫,然 後於週邊溫度攪拌16小時。然後用冷水稀釋,用醋酸乙酯 萃取二次。合併之有機相於MgS〇4上乾燥,過濾及蒸發。殘 餘物作閃色層分析(二氧化矽膠;洗離劑:己烷及醋酸乙酯 梯度),得 0.413 克(84%) rac-3-{1_[2_(3,5-二甲氧基苯基)·5_ 甲 基-噚唑-4-基甲基]-1Η-吲哚-4-基}_2_乙氧基_丙酸乙基酯, 為淺黃色固體。 MS : 493.3 (Μ + Η)+。 卜[2-(^:—士 甲_^^^5_ 甲某-啐神,4,^_ 嗓 _ 4 _ 基} _ 2 -乙氣 酸 將Μ(^3-{1-[2-(355-二甲氧基-苯基)甲基^号唑_4_基甲 基]·1Η-β哚-.4-基卜2-乙氧基-丙酸乙基酯(〇·39〇克,〇·79毫莫 耳)/合於15¾升二呷烷内;然後於室溫加198毫升Li〇H水溶 液(1.0莫耳的,丨.98毫莫耳)。所得混合物於室溫攪拌過夜, ^後倒於冰上,用HCU1N)中和至pH4,用MeCb萃取三次。 合併之有機相用水洗,於MgS〇4上乾燥,過濾及蒸發,得〇·242 克⑽…^^七-㈤-二甲氧基-苯基卜^甲基-口号唑-心基 甲基]1Η-吲哚_各基}-2-乙氧基,酸,為淺黃色固體。 MS : 465.3 (Μ+Η)+。 89200 ^39- 200413357 n c - 2 _乙氧基_ 3 _ {丄^丄? _ (4 一 g s Ά 朴甘、广 号唑冬其甲 基J-lH-啕哚-4-幕丄^丙酸 - 以類似實例1 a]及b]工序, 斤j r*ac-2-乙乳基-3 η 基)-丙酸乙基醋與4_氯甲基,4_異丙基_苯基)1甲… 在N,N_二/基甲酸胺内在有氫化納之存在下反應,製得 rac-2-乙氧基-M W2_(4_異丙基_苯基)_5-甲基 基㈣,_4·基卜丙酸乙基酷,此再作息化,即得racI 乙乳基-3-{l-[2-(4-異丙基_笨基)_5_甲基-嘮唑_心基甲 基卜汨^丨哚-4-基卜丙酸,為淺綠色固體。 土 MS : 447.3 (M+H)+ 〇 乙氧基- 3-{ 1二「3-(5-ο菜其广u / η 乙某 i-iH- 啕哚-4-某丨-丙酸 - 以類似實例1 a]及b]工序,9 产 A 用 raC-2_ 乙氧基-3、(1Η-4 哚-4- 基)-㈣乙基酉旨與甲燒續酸3♦甲基_2_苯基H4_基丙 基酯在N,N-二甲基甲醯胺内在有氫化鈉之存在下反應,製 得mc-2-乙氧基-3] 1-[3-(5_甲基j苯基^号唑基)-丙 基]”哚-4-基}-丙酸乙基酯,此再作皂化,即得账2_ 乙氧基_3_{ 1-[3_(5-甲基1苯基』号唑基)_丙基卜1H_⑷哚 -4-基卜丙酸,為淺棕色油體。 MS : 433.4 (M+H)、 實例4 L§c-2 -乙氧基- 3-{M2-f5 -甲 - 口咢唑-4-甚)Γ」某卜 1H-89200 -40- 200413357 卩引口果_ 4 _基卜丙酸 以類似實例1 a]及b)工序,用rac-2-乙氧基-3-(1Η-啕哚-4-基)-丙酸乙基酯與甲烷績酸2-(5-甲基-2-苯基j号唑-4-基)-乙基酯在N,N-二甲基甲醯胺内在有氫化鈉之存在下反應, 製得rac-2-乙氧基-3-{l-[2-(5-甲基-2-苯基-$咬_4-基)乙 基]-1H-吲嗓-4-基}-丙酸乙基酯,此再行皂化,即得rac-2-乙氧基-3-{1-[2-(5-甲基-2-苯基-呤唑-4-基)乙基]-1H-啕哚 -4-基} 丙酸’為淺黃色固體。 MS : 417.3 (M-H)、 實例5 rac^^. 氧基-3_-1>(5-[基-2-茉某-呤峻二^基甲某V1H、丨 嗓-4-基1-丙酸 以類似貫例1 a]及b)工序,用rac-2-乙氧基-3-( 1H- Θ丨嗓-4-基)-丙酸乙基酯與4-氯甲基-5—甲基_2_苯基号唑在N,N•二甲 基甲醯胺内在有氧化鈉之存在下反應,製得rac_2_乙氧基 -3-[l-(5-甲基-2-苯基j号唑_4-基甲基卜丨乩吲哚-‘基卜丙酸 乙基酯,此再行包化即製得rac_2_乙氧基·3_[1-(5-甲基_2_苯 基j亏唑基甲基)-1Η-ρ?丨哚_4_基]_丙酸,為灰白色固體。 MS : 403·3 (Μ-Η)、 貫例6 :笨基)士甲基-啐唑_4_其甲 基1-1H:啕j - 4-某卜而色 以〆員似兵例1 a]及b]工序,用rac_2_乙氧基一3_(出_口弓丨哚_4_ 基)-丙酸乙基酯與4-氣甲基氟-苯基)_5_甲基^号唑在 89200 -41 - 200413357 N,N-二甲基甲酿胺内在有氫化鈉之存在下反應,製得rac_2_ 乙氧基-3-{l-[2-(2-氟苯基)_5_甲基^咢咬-4-基甲基]-1H-4丨嗓 -4-基}-丙酸乙基酯,此再行皂化即製得rac_2_乙氧基 -3-{ 1-[2-(2-氟苯基)-5-甲基-噚唑_4_基甲基]-1H-W哚-4-基}- 丙酸,為灰白色固體。 MS : 421·2 (M-H)、 實例7 rac-3-fl-「又:12-氯-苯甲某-啐岫基甲基㈤哚 _ 4 -基卜丙 以類似實例1 a]及b)工序,用rac_i乙氧基_3·(1Η_Ρ?丨哚-4_ 基)-丙酸乙基酯與4-氣甲基-2-(2-氣-苯基)-5-甲基号唑在 Ν,Ν-二甲基甲醯胺内在有氫化鈉之存在下反應,製得 rac-3-{l-[2-(2-氣-苯基)-5-甲基号唑_4_基甲基]-1Η-喇哚_4_ 基}-2-乙氧基-丙酸乙基醋,此再行皂化即製得 rac-3-{ 1-[2-(2-氯-苯基)-5-甲基_嘮唑基甲基]-1Η-吲哚-4- 基} -2-乙氧基-丙酸,為淺棕色固體。 MS : 437.2 (M-H)、 實例8 rac-2-乙氧.甲基甲笨基二^唑-4-某甲 基)- 1H -口弓j 口朵-4-基丙齡 以類似貫例1 a]及b]工序,用rac_2·乙氧基-3-(lH-吲嗓-4-基)-丙酸乙基醋與4-氣甲基-5-甲基甲苯基j号唑在N,N-二甲基甲醯胺内在有氫化鈉之存在下反應,製得rac-2_乙氧 基-3-[l-(5-甲基-2-0-甲苯基-啰唑_4_基甲基)_1H、丨哚_4_基卜 -42- 89200 200413357 丙酸乙基酯,此再扞❾仆P制 仃七化即製得rao2-乙氧基1-(5-甲基 -2 _ 〇 -甲 - 口亏 口坐-4 - tt 田曾、” 土甲基)-1Η-吲哚-4-基卜丙酸,為淺棕色 油體。 MS : 417.3 (M-H)· 〇 tJl9_ -p咢峻二4 -某甲 rac- 3- { 1-[2-(3 -氧^ -4 -基卜2-乙氧基-¾够 以頒似貝例1 a]及b]工序,用rac_2_乙氧基士(1H J哚j 基)-丙酸乙基酯與心氣甲基七Ο务苯基)_5•甲基唑在 N,N-二甲基甲醯胺内在有氫化納之存在下反應,製得 rac-3-(卜[2-(3-氣-苯基)_5_甲基号唑基甲基>ιΗ、丨哚 基)-2-乙氧基-丙酸乙基酯,此再行息化即製得 raC-3-{l-[2-(3-氣-苯基)-5_甲基_咩唑_4·基甲基]_ih、丨哚_‘ 基}-2-乙氧基-丙酸,為棕色固體。 MS : 437.2 (M-H)、 f例1 0 rap-2-乙.氧基 甲基V 1Η - Μ]嘴-4 -基}-丙酸 以類似貫例1 a]及b]工序,用rac-2-乙氧基_3_( 丨嗓-4-基)-丙酸乙基酯與4-氣甲基-5-甲基-2-(‘三氟甲基苯基)-哼 。坐在_-二甲基甲隸内在有氫化納之存在下反應,製得 rac-2-乙氧基-3-(l-[5-甲基-2-(4-三氟T基_苯基)-十坐-心基 曱基]-1Η^|味-4-基)-丙酸乙基酿,此再行息化 " 乙氧基·3·{ i_[5-曱基-2-(4-三敗曱基_笨基}_ϋ ^2- 89200 -43 - 200413357 基]-1 Η- 4丨嗓-4-基}-丙酸,為白色固體。 MS : 471.3 (M-Η)·。 實例1 1 乙氧基-3-{ 1-[2·甲基^三氟甲某-苽篡V咩唑-4-基_ 甲基1 -1 Η - 4丨嗓-4 -基}-丙酸 以類似貫例1 a]及b]工序,用rac>2-乙氧基-3-( ιη_ Θ卜朵-4-基)-丙酸乙基酯與4-氯甲基-2-(4-氟-3-甲基-苯基)-5-甲基_ ’峻在N,N-二甲基甲醯胺内在有氫化鈉之存在下反應,製 知rac-2-乙氧基- 3-{l-[2-(4-氟-3-甲基-苯基)_5~甲基-口号峻-4-基甲基]-1H-4丨嗓-4-基}•丙酸乙基酯,此再行皂化即製得 rac-2-乙氧基-3- {1-[2-(4-氟-3 -甲基-苯基)-5-甲基口坐_4-基 甲基]-1H-4丨嗓-4-基}-丙酸,為灰白色固體。 MS ·· 437·3 (M+H)+。 實例1 2 乙氧基-3_{ 1-[2二(.4-異丙氣基·笨基)-5 -甲篡-口等。坐-4-墓 甲基丨·1Η-β卜朵-4-基丙醢 以類似實例1 a]及b]工序,用rac_2-乙氧基- 3-( 1Η-卩?丨嗓- 4-基)-丙酸乙基酯與4-氯甲基-2-(4-異丙氧基-苯基)-5-甲基-吟唑在N,N-二甲基甲醯胺内在有氧化鈉之存在下反應,製 得rac-2·乙氧基-3-(l-[2-(4-異丙氧基-苯基)-5-甲基-口号口坐-ζμ 基甲基]-1H- 4丨嗓-4-基)-丙酸乙基醋,此再行皂化即製得 i*ao2-乙氧基-3-{卜[2-(4_異丙氧基-苯基)_5-甲基号唑-‘基 甲基]-1H-4卜朵-4-基卜丙酸,為淺黃色固體。 MS ·· 463.3 (M+H)+。 -. -44- 89200 200413357 實例1 3 rac-2-乙氣基-3-丨142-(4-異丙氣基-笨某唑-4-基甲 基丨哚-4-基卜丙酸 以類似實例1 a]及b]工序,用rac-2-乙氧基-3-(1Η-θ丨哚-4-基)-丙酸乙基酯與4-氯曱基-2-(4-異丙基-苯基)-嘮唑在Ν,Ν-二甲基甲醯胺内在有氫化鈉之存在下反應,製得rac-2-乙氧 基- 3- {l-[2-(4-異丙基-琴基)号哇-4-基甲基]-1 Η- 丨嗓-4 -基} _ 丙酸乙基酯,此再行皂化即製得rac-2-乙氧基-3-{l-[2-(4-異 丙基-苯基)·-号唑-4-基甲基]-1H-吲哚-4-基卜丙酸,為棕黃色 固體。 MS : 449.3 (M + H)+。
實例A 含下述成分的錠可以習用方式製造: 成分 每錠 式I化合物 10.0-100.0 毫克 乳糖 125.0毫克 玉米澱粉 7.5毫克 滑石粉 4.0毫克 硬脂酸鎂 1 .〇毫克 實例B 含下述成分的膠囊可以習用方式製造: 成分 每膠囊 式I化合物 25.0毫克 乳糖 150.0毫克 玉米殿粉 20.0毫克 滑石粉 5.0毫克 89200 -45 - 200413357 實例c 含下述成分的注射溶液可以習用方式製造 式I化合物 3.0毫克 明膠 150.0毫克 碳酸鈉 加至終pH為7 酚 4.7毫克 注射用水 加至1.0毫升 89200 -46 -
Claims (1)
- 200413357 拾、申请專利範圍· 1· 一種下式化合物其中 R1是芳基或雜芳基; R2是氫,烷基或環烷基; R3是烷氧基或經一至三個鹵素原子取代的烷氧基; R疋氣’燒基或環燒基; A是氧或疏; η是1,2或3 ; 及,其中碳原子ca&cb間的鍵是碳碳單鍵或雙鍵; 及其醫藥上可接受的鹽與酯。 2·根據申請專利範圍第i項之化合物,其中Rl是苯基或以一 至三個取代基取代的苯基,此等取代基是獨立選自烷氧 基,烷基,鹵素及以一至三個_素原子取代的烷基。 3’根據申請專利範圍第1或2項之化合物,其中尺]是苯基, 二甲氧基苯基,異丙基-苯基,氟-苯基,氣_苯=〇基 -苯基,三氟甲基-苯基,甲基_氟-苯基或異丙氧基_苯基。 89200 200413357 4. 根據申請專利範圍第1或2項之化合物,其中R2是氫,甲 基或乙基。 5. 根據申請專利範圍第4項之化合物,其中R2是甲基。 6. 根據申請專利範圍第1或2項之化合物,其中R3是甲氧基 或乙氧基。 7. 根據申請專利範圍第1或2項之化合物,其中R4是氫。 8. 根據申請專利範圍第1或2項之化合物,其中碳原子Ca及 Cb間的键是碳碳單键。 9. 根據申請專利範圍第1或2項之化合物,其中η是1或3。 10. 根據申請專利範圍第1或2項之化合物,其中Α是氧。 11. 根據申請專利範圍第1或2項之化合物是選自: rac-3-{l-[2-(3,5-二甲氧基-苯基)-5-甲基-嘮唑-4-基甲 基]-1H-吲哚-4-基卜2-乙氧基丙酸; mc-2-乙氧基-3-{1-[2-(4-異丙基-苯基)-5-甲基-嘮唑-4-基 甲基]-1H、丨哚-4-基卜丙酸; mc-2-乙氧基-3-{l-[3-(5-甲基-2-苯基-呤唑-4-基)丙基] -1H-W哚-4-基卜丙酸; rac-2-乙乳基-3-{l-[2-(5-甲基-2-表基-p号口坐-4-基)乙 基]哚-4-基卜丙酸; rac-2-乙氧基- 3·[1-(5-甲基-2-本基-口号口坐-4-基甲基)-1 H- 口弓丨 嗓-4 -基]-丙, rac-2-乙氧基-3-{l-[2-(2-氟-苯基)-5-甲基-嘮唑-4-基甲基] -1H-口弓丨哚-4-基}-丙酸; rac-3-{l-[2-(2-氯-苯基)-5-甲基-口号唑-4-基甲基]-1Ή-Μ丨哚 89200 200413357 _4-基}-乙乳基-丙酸, rac-2-乙氧基-3-[l-(5-甲基-2-0-甲苯基-吟唑-4-基甲 基)-1Η-啕哚-4-基]-丙酸; 以〇3-{1-[2-(3-氯-苯基)-5-甲基-嘮唑-4-基甲基]-11^4卜朵 -4 -基}-乙氧基··丙故, rac-2-乙氧基-3-{l-[5-甲基-2-(4-三氟甲基-苯基)-呤唑-4-基甲基]-1H-啕哚-4-基卜丙酸; rac-2-乙氧基-3-{l-[2-(4-氣-3 -甲基-苯基)-5-甲基-口号口坐-4 -基甲基]-1H-4丨嗓-4-基}•丙酸, rac- 2-乙乳基-3-{l-[2-(4-異丙氧基-苯基)-5-甲基-卩亏口坐-4·~ 基甲基]-1Η-吲哚-4-基}-丙酸;及 rac-2-乙氧基-3-{1-[2-(4-異丙基-苯基)-口塞峻-4-基甲 基]-1Η、丨哚-4-基卜丙酸。 12. 根據申請專利範圍第11項之化合物是選自: rac-3-{l-[2-(3,5-二甲氧基-苯基)-5-甲基-呤唑-4-基甲 基]-1H-啕哚-4-基卜2·乙氧基丙酸; mc-2-乙氧基-3-{1-[3-(5-甲基-2-苯基-哼唑-4-基)丙 基]-1H-啕哚-4-基}-丙酸;及 rac-2-乙乳基-3-{l-[2-(4-氣-3-甲基-苯基)-5-甲基-口号口坐-4_ 基甲基]哚-4-基卜丙酸。 13. —種製備根據申請專利範圍第1或2項之化合物的方法, 其包括下述反應之一 a)以下式化合物 89200 200413357(8) 在有下式化合物之存在下反應(3) 其中R1至R4,A及η之定義如申請專利範圍第所述,X 是鹵素或CHsSO3,R是烷基,芳基或芳烷基,及其中 Cb碳原子間的鍵是碳碳單键或雙鍵; b)將下式化合物氫化14. 15. /、 R至R,A及η之定義如申請專利範圍第丨項所述。 根據申請專利範圍第丨或2項之化合物,其係用作治療活 性物質。 根據申請專利範圍第1或2項之化合物,用於製·備藥物供 89200 200413357 預防及/或治療以PPARoc及/或pPARy激動劑調節的疾病。 16· —種醫藥組合物,其含根據申請專利範圍第丨或2項之化 合物及治療惰性載劑。 17·根據申請專利範圍第16項之醫藥組合物,其尚含治療有 效量的脂酶抑制劑。 队根據申請專利範圍第π項之醫藥組合物,其中脂酶抑制 劑是奥利司他(orlistat)。 19· 一種根據申請專利範圍第丨或2項之化合物在製備供治療 及/或預防以PPARa及/或ΡΡΑΙΙγ激動劑調節的疾病之藥物 之用途。 2〇·根據申請專利範圍第i或2項之化合物,其係根據申請專 利範圍第13項之方法製備。· " 21·根據中請專利範圍第16項之醫藥組合物,其係用於治療 及/或預防以ppARa& /或PPARy激動劑調節的疾病。 22· 一種根據申請專利範圍第2項之化合物在製備供用於 也接文脂酶抑制劑治療之病人以治療及/或預防以 PPARa及/或ΡΡΑΚγ激動劑調節的疾病之藥物的用途。 23·根據巾請專利範圍第25項之用it,其中脂酶抑制劑是奥 利司他。 24.^據申請專利範圍第19或22項之用途,其中疾病是糖尿 病非胰島素依賴型糖尿病,高血壓,高脂及膽固醇, 動脈粥樣硬化疾病或代謝病徵。 25·根據中請專利^圍第μ項之錢,其 依賴型糖尿病。 疋非胰島素 89200 200413357 26. 根據,申·請專利範圍第21項之醫藥組合物, 尿病,非胰島素依賴型糖尿病,高血壓,ί 動脈粥樣硬化疾病或代謝病徵。 27. 根據申請專利範圍第26項之醫藥組合物, 胰島素依賴型糖尿病。 其中疾病是糖 脂及膽固醇, 其中疾病是非 89200 200413357 柒、指定代表圖: (一) 本案指定代表圖為:第()圖。 (二) 本代表圖之元件代表符號簡單說明: 捌、本案若有化學式時,請揭示最能顯示發明特徵的化學式:89200
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02026366 | 2002-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200413357A true TW200413357A (en) | 2004-08-01 |
Family
ID=32338000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092132418A TW200413357A (en) | 2002-11-25 | 2003-11-19 | Indolyl derivatives |
Country Status (21)
Country | Link |
---|---|
US (1) | US7098228B2 (zh) |
EP (1) | EP1567523B1 (zh) |
JP (1) | JP4384052B2 (zh) |
KR (1) | KR100713266B1 (zh) |
CN (1) | CN100343250C (zh) |
AR (1) | AR042117A1 (zh) |
AT (1) | ATE405560T1 (zh) |
AU (1) | AU2003292030B2 (zh) |
BR (1) | BR0316556A (zh) |
CA (1) | CA2505545C (zh) |
DE (1) | DE60323130D1 (zh) |
ES (1) | ES2312819T3 (zh) |
GT (1) | GT200300251A (zh) |
MX (1) | MXPA05005445A (zh) |
PA (1) | PA8589401A1 (zh) |
PE (1) | PE20040843A1 (zh) |
PL (1) | PL377320A1 (zh) |
RU (1) | RU2315767C2 (zh) |
TW (1) | TW200413357A (zh) |
UY (1) | UY28091A1 (zh) |
WO (1) | WO2004048371A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050203151A1 (en) * | 2003-12-19 | 2005-09-15 | Kalypsys, Inc. | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions |
CA2676944C (en) * | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4011326A (en) | 1975-07-29 | 1977-03-08 | Merck & Co., Inc. | 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents |
DE3034005C2 (de) | 1980-09-10 | 1982-12-09 | A. Nattermann & Cie GmbH, 5000 Köln | Indolessigsäure-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
JPH07508747A (ja) | 1992-07-03 | 1995-09-28 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 医薬用複素環化合物 |
GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
DE4317320A1 (de) | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
JPH09176162A (ja) * | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
ATE277037T1 (de) * | 1996-07-09 | 2004-10-15 | Nikem Research Srl | Indolderivate zur behandlung von osteoporose |
TW476758B (en) | 1996-12-10 | 2002-02-21 | Bristol Myers Squibb Co | Benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane melatonergic agents |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
DE19711616A1 (de) | 1997-03-20 | 1998-09-24 | Boehringer Mannheim Gmbh | Verbessertes Verfahren zur Herstellung von Thiazolidindionen |
US6121397A (en) | 1997-07-14 | 2000-09-19 | Xerox Corporation | Polymerization processes using oligomeric compound, monomer and surfactant |
HN1998000118A (es) | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
ES2200248T3 (es) | 1997-09-19 | 2004-03-01 | Ssp Co., Ltd. | Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen. |
DE69828445D1 (de) | 1998-04-23 | 2005-02-03 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
GB9817118D0 (en) | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
JP3761783B2 (ja) | 1998-08-14 | 2006-03-29 | エフ.ホフマン−ラ ロシュ アーゲー | リパーゼ阻害剤とキトサンを含む製薬学的組成物 |
PT1105122E (pt) | 1998-08-14 | 2005-08-31 | Hoffmann La Roche | Composicoes farmaceuticas que contem inibidores de lipase |
GB9902459D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
DK1078923T3 (da) | 1999-08-02 | 2006-07-10 | Hoffmann La Roche | Fremgangsmåde til fremstilling af benzothiophenderivater |
MXPA02007099A (es) * | 2000-01-19 | 2004-08-23 | Alteon Inc | Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina. |
CN1471517A (zh) | 2000-08-23 | 2004-01-28 | Cxazolyl-芳基丙酸衍生物及其作为过氧化物酶体增殖物活化受体激动剂的用途 | |
KR20030030036A (ko) * | 2000-09-29 | 2003-04-16 | 시오노기세이야쿠가부시키가이샤 | 티아졸 또는 옥사졸 유도체 |
ES2264482T3 (es) * | 2001-05-15 | 2007-01-01 | F. Hoffmann-La Roche Ag | Derivados de oxazol sustituidos por acido carboxilico para uso como activadores de ppar-alfa y gamma en el tratamiento de diabetes. |
WO2003005025A1 (en) | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
US6903104B2 (en) * | 2001-12-06 | 2005-06-07 | National Health Research Institutes | Indol-3-YL-2-oxoacetamide compounds and methods of use thereof |
TWI317634B (en) * | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
WO2003053976A1 (en) | 2001-12-20 | 2003-07-03 | Biovitrum Ab | PIPAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR |
-
2003
- 2003-11-17 DE DE60323130T patent/DE60323130D1/de not_active Expired - Lifetime
- 2003-11-17 WO PCT/EP2003/012814 patent/WO2004048371A1/en active IP Right Grant
- 2003-11-17 AT AT03767555T patent/ATE405560T1/de active
- 2003-11-17 EP EP03767555A patent/EP1567523B1/en not_active Expired - Lifetime
- 2003-11-17 BR BR0316556-6A patent/BR0316556A/pt not_active Withdrawn
- 2003-11-17 AU AU2003292030A patent/AU2003292030B2/en not_active Ceased
- 2003-11-17 RU RU2005120152/04A patent/RU2315767C2/ru not_active IP Right Cessation
- 2003-11-17 CN CNB2003801041013A patent/CN100343250C/zh not_active Expired - Fee Related
- 2003-11-17 MX MXPA05005445A patent/MXPA05005445A/es active IP Right Grant
- 2003-11-17 JP JP2004554364A patent/JP4384052B2/ja not_active Expired - Lifetime
- 2003-11-17 KR KR1020057009337A patent/KR100713266B1/ko not_active IP Right Cessation
- 2003-11-17 ES ES03767555T patent/ES2312819T3/es not_active Expired - Lifetime
- 2003-11-17 PL PL377320A patent/PL377320A1/pl not_active Application Discontinuation
- 2003-11-17 CA CA2505545A patent/CA2505545C/en not_active Expired - Fee Related
- 2003-11-19 TW TW092132418A patent/TW200413357A/zh unknown
- 2003-11-21 AR ARP030104311A patent/AR042117A1/es not_active Application Discontinuation
- 2003-11-21 PE PE2003001184A patent/PE20040843A1/es not_active Application Discontinuation
- 2003-11-21 PA PA20038589401A patent/PA8589401A1/es unknown
- 2003-11-21 GT GT200300251A patent/GT200300251A/es unknown
- 2003-11-21 US US10/719,556 patent/US7098228B2/en not_active Expired - Fee Related
- 2003-11-24 UY UY28091A patent/UY28091A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ES2312819T3 (es) | 2009-03-01 |
JP2006513173A (ja) | 2006-04-20 |
JP4384052B2 (ja) | 2009-12-16 |
CN100343250C (zh) | 2007-10-17 |
DE60323130D1 (de) | 2008-10-02 |
KR100713266B1 (ko) | 2007-05-04 |
PE20040843A1 (es) | 2004-12-24 |
PA8589401A1 (es) | 2004-07-20 |
RU2315767C2 (ru) | 2008-01-27 |
AU2003292030A1 (en) | 2004-06-18 |
CA2505545A1 (en) | 2004-06-10 |
ATE405560T1 (de) | 2008-09-15 |
UY28091A1 (es) | 2004-05-31 |
WO2004048371A1 (en) | 2004-06-10 |
AU2003292030B2 (en) | 2007-01-04 |
MXPA05005445A (es) | 2005-08-26 |
US7098228B2 (en) | 2006-08-29 |
EP1567523B1 (en) | 2008-08-20 |
PL377320A1 (pl) | 2006-01-23 |
CA2505545C (en) | 2011-06-07 |
BR0316556A (pt) | 2005-10-04 |
GT200300251A (es) | 2004-06-28 |
EP1567523A1 (en) | 2005-08-31 |
AR042117A1 (es) | 2005-06-08 |
RU2005120152A (ru) | 2006-05-27 |
KR20050086759A (ko) | 2005-08-30 |
CN1717407A (zh) | 2006-01-04 |
US20040106657A1 (en) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI359148B (zh) | ||
CN101772487B (zh) | 甲状腺类化合物 | |
HRP20050212A2 (en) | N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes | |
WO1999046232A1 (fr) | Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif | |
TW200804317A (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
WO2000023442A1 (fr) | Derives d'acide carboxylique et medicaments contenant ces derives en tant que principe actif | |
WO2000012491A1 (fr) | Derives d'acide carboxylique et medicaments dont ils sont le principe actif | |
TW200413357A (en) | Indolyl derivatives | |
RU2295520C2 (ru) | ПРОИЗВОДНЫЕ ОКСАЗОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ СЕНСИБИЛИЗАТОРОВ ИНСУЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ В ОТНОШЕНИИ PRARα И/ИЛИ PRARγ | |
TW200813071A (en) | Spiro-imidazo compounds | |
JP2001122865A (ja) | ベンゾチアゾロン誘導体 |